Jim Cramer's Stop Trading: GW Pharmaceuticals Is 'A Winner'

NEW YORK (TheStreet) -- Shares of GW Pharmaceuticals (GWPH) are trading higher following the pricing of the company's secondary stock offering. 

The company plans to sell 1.7 million shares at $86.83, according to TheStreet's Jim Cramer, co-manager of the Action Alerts PLUS portfolio

On CNBC's "Cramer's Stop Trading" segment, he said that many investors thought the secondary offering would put a halt to the recent rally.

However, this stock is "a winner," he reasoned, saying that most doctors who look to prescribe a cannabinoid treatment "have a hard time trusting any other brand" -- making GW Pharmaceuticals stand out.

"This will replace Oxycodone, that's my prediction," Cramer said in regards to pain management via cannabis-related treatments. 

GW Pharmaceuticals is "not a penny stock or a marijuana stock," he concluded, it's "a pain-killing company." 

-- Written by Bret Kenwell in Petoskey, Mich.

Adobe, FedEx Hit All-Time Highs on Strong Earnings

Sneakers at Work Are Running Up Sales for Nike, Foot Locker

Prestigious Cancer Hospital Rebukes Northwest Bio for 'Inappropriate' Data Disclosures

Home Short-Sellers Could Face a Huge Hidden Tax

At the time of publication, Cramer's Action Alerts PLUS had no position in companies mentioned.

More from Opinion

Apple Needs to Figure Out Its Self-Driving Vehicle Strategy

Apple Needs to Figure Out Its Self-Driving Vehicle Strategy

Throwback Thursday: Tesla, Chip Stocks, TheStreet's Picks

Throwback Thursday: Tesla, Chip Stocks, TheStreet's Picks

12 Stocks That Our Writers and Their Sources Recommend You Buy Here

12 Stocks That Our Writers and Their Sources Recommend You Buy Here

Musk Goes on Unoriginal Media Tirade

Musk Goes on Unoriginal Media Tirade

What's Happening in Video Games This Week: On the Road to E3

What's Happening in Video Games This Week: On the Road to E3